Chinese expert consensus on the diagnosis and treatment of malignant pleural mesothelioma.
Wang Q, Xu C, Wang W, Zhang Y, Li Z, Song Z, Wang J, Yu J, Liu J, Zhang S, Cai X, Li W, Zhan P, Liu H, Lv T, Miao L, Min L, Li J, Liu B, Yuan J, Jiang Z, Lin G, Chen X, Pu X, Rao C, Lv D, Yu Z, Li X, Tang C, Zhou C, Zhang J, Guo H, Chu Q, Meng R, Liu X, Wu J, Hu X, Zhou J, Zhu Z, Chen X, Pan W, Pang F, Zhang W, Jian Q, Wang K, Wang L, Zhu Y, Yang G, Lin X, Cai J, Feng H, Wang L, Du Y, Yao W, Shi X, Niu X, Yuan D, Yao Y, Huang J, Wang X, Zhang Y, Sun P, Wang H, Ye M, Wang D, Wang Z, Hao Y, Wang Z, Wan B, Lv D, Yu J, Kang J, Zhang J, Zhang C, Wu L, Shi L, Ye L, Wang G, Wang Y, Gao F, Huang J, Wang G, Wei J, Huang L, Li B, Zhang Z, Li Z, Liu Y, Li Y, Liu Z, Yang N, Wu L, Wang Q, Huang W, Hong Z, Wang G, Qu F, Fang M, Fang Y, Zhu X, Du K, Ji J, Shen Y, Chen J, Zhang Y, Ma S, Lu Y, Song Y, Liu A, Zhong W, Fang W.
Thorac Cancer. 2023 Sep;14(26):2715-2731. doi: 10.1111/1759-7714.15022. Epub 2023 Jul 17.
Engineered lactococcus lactis intrapleural therapy promotes regression of malignant pleural effusion by enhancing antitumor immunity.
Fan Y, Chen A, Zhu J, Liu R, Mei Y, Li L, Sha X, Wang X, Ren W, Wang L, Liu B.
Cancer Lett. 2024 Apr 28;588:216777. doi: 10.1016/j.canlet.2024.216777. Epub 2024 Mar 2.
Intrapleural dual blockade of IL-6 and PD-L1 reprograms CAF dynamics and the tumor microenvironment in lung cancer-associated malignant pleural effusion.
Cheng Q, Zuo X, Wang Z, Lu W, Jiang Y, Liu J, Li X, Xu Q, Zhu S, Liu X, Song Y, Zhan P, Lv T.
Respir Res. 2025 May 10;26(1):180. doi: 10.1186/s12931-025-03263-0.
Clinical features and risk factors of invasive pulmonary aspergillosis in interstitial lung disease patients.
Liu Y, Jiang H, Zhao T, Cao M, He J, Qi R, Xiao Y, Su X.
BMC Pulm Med. 2024 Dec 4;24(1):602. doi: 10.1186/s12890-024-03430-x.
Updated perspectives on visceral pleural invasion in non-small cell lung cancer: A propensity score-matched analysis of the SEER database.
Liu J, Wang Y, Zhou X, Reng M, Xiang Z, Chang R, Hao W, Sun X, Yang Y.
Curr Probl Cancer. 2025 Jun;56:101205. doi: 10.1016/j.currproblcancer.2025.101205. Epub 2025 Apr 18.
Anlotinib enhances the anti-tumor activity of osimertinib in patients with non-small cell lung cancer by reversing drug resistance.
Hua X, Wu X, Lv L, Gu Y, Zhu S, Liu X, Lv T, Song Y.
Transl Lung Cancer Res. 2025 Jan 24;14(1):40-57. doi: 10.21037/tlcr-24-759. Epub 2025 Jan 20.
Intrapleural Injection of Anti-PD1 Antibody: A Novel Management of Malignant Pleural Effusion.
Li X, Wu G, Chen C, Zhao Y, Zhu S, Song X, Yin J, Lv T, Song Y.
Front Immunol. 2021 Dec 13;12:760683. doi: 10.3389/fimmu.2021.760683. eCollection 2021.
[Analysis of risk factors of multiple fractures of limbs complicated with pleural effusion].
Tan L, Zhang ZT, Qiu XS, Chen YX.
Zhongguo Gu Shang. 2022 Jul 25;35(7):692-7. doi: 10.12200/j.issn.1003-0034.2022.07.019.
Activation and propagation of tumor-infiltrating lymphocytes from malignant pleural effusion and ascites with engineered cells for costimulatory enhancement.
Xu Q, Shao J, Su S, Wei J, Chen F, Meng F, Zhao Y, Du J, Zou Z, Qian X, Liu B.
Cell Immunol. 2018 Sep;331:1-8. doi: 10.1016/j.cellimm.2018.04.006. Epub 2018 Apr 17.
Risk factors of incident lung diseases and the impact of DMARDs in rheumatoid arthritis patients: a longitudinal study.
Chen G, Zhang Q, Geng L, Zhang Y, Liang J, Jin Z, Qian Z, Xu X, Zhu K, Shu Q, Tang X, Zhang H, Feng X, Chen H, Wang D, Sun L, Shen W.
BMC Pulm Med. 2025 Nov 3;25(1):504. doi: 10.1186/s12890-025-03915-3.
